Results 71 to 80 of about 23,486 (164)

Fondaparinux [PDF]

, 2020
openaire   +1 more source

Fondaparinux vs warfarin for the treatment of unsuspected pulmonary embolism in cancer patients

Drug Design, Development and Therapy, 2016
Bruno Amato,1,2,* Rita Compagna,1,2,* Aldo Rocca,2 Tommaso Bianco,2 Marco Milone,2 Luigi Sivero,2 Gabriele Vigliotti,2 Maurizio Amato,2 Michele Danzi,2 Giovanni Aprea,2 Luca Gallelli,3,* Stefano de Franciscis,1,4,* Raffaele Serra1,4,* 1Interuniversity ...
Amato B, Compagna R, Rocca A, Bianco T, Milone M, Sivero L, Vigliotti G, Amato M, Danzi M, Aprea G, Gallelli L, de Franciscis S, Serra R   +12 more
doaj  

The clinical course of symptomatic deep vein thrombosis after 3 months of anticoagulant therapy using fondaparinux/edoxaban or fondaparinux/vitamin K antagonist

Therapeutics and Clinical Risk Management, 2018
Kazuhiro Shimizu, Takuo Iiduka, Shuji Sato, Hajime Kiyokawa, Takahiro Nakagami, Hiroshi Mikamo, Masayo Kawazoe, Mao Takahashi, Mahito Noro Department of Internal Medicine, Toho University Sakura Medical Center, Sakura City, Chiba, Japan Background: For
Shimizu K, Iiduka T, Sato S, Kiyokawa H, Nakagami T, Mikamo H, Kawazoe M, Takahashi M, Noro M   +8 more
doaj  

Comparative effectiveness of parenteral anticoagulants (fondaparinux, argatroban, bivalirudin) in heparin-induced thrombocytopenia: A systematic review. [PDF]

World J Methodol
Rehman A, Abid M, Jamil H, Siddique S, Parkash S, Nasrullah F, Sapna F, Lohana B, Lohana K, Jawed I, Tufail M, Sharaf MS.   +11 more
europepmc   +1 more source

Disproportionality analysis of fondaparinux associated adverse events based on the FDA adverse event reporting system. [PDF]

PLoS One
Kang F, Wang Y, Cai F, Wu L, Han L, Yin Q, Bian Y.   +6 more
europepmc   +1 more source

Adverse event profile of fondaparinux sodium: a disproportionality analysis based on FAERS, JADER, and VigiAccess databases. [PDF]

Front Med (Lausanne)
Jin W, Pan J, Yu L, Zhu M.
europepmc   +1 more source

Anticoagulation for Cancer Patients in Special Situations: A Narrative Review of Guidelines and Literature. [PDF]

Cancers (Basel)
Sotoca Rubio P, Serrano Domingo JJ, Guerrero Serrano P, Pérez de Aguado Rodríguez P, Barrill Corpa AM, Moreno Doval J, García de Quevedo Suero C, Calvo Pérez JC, González-Merino C, González Martín G, Chamorro Pérez J, Gómez Rueda A, Garrido López P.   +12 more
europepmc   +1 more source

Safety Profile and Bleeding Complications of Fondaparinux Versus Enoxaparin in Non-ST Elevation Acute Coronary Syndrome. [PDF]

Cureus
Rahman MM, Ahmed FU, Chowdhury MI, Noor H, Hossain MA.   +4 more
europepmc   +1 more source

Safety of Fondaparinux After Low-Molecular-Weight Heparin in Bleeding-Complicated High-Risk Pregnancies: A PSM Cohort Study. [PDF]

Int J Womens Health
Yang H, Gao Y, Song X.
europepmc   +1 more source

Radial Access and Fondaparinux: A Synergistic Interaction. [PDF]

Arq Bras Cardiol
Andrade PB, Silva LMA.
europepmc   +1 more source